Rudy Birsen
Overview
Explore the profile of Rudy Birsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalife-Hachem S, Pages A, Akoury E, Bonnet S, Birsen R, Busquet C, et al.
Blood Adv
. 2024 Dec;
9(4):793-796.
PMID: 39642332
No abstract available.
2.
Pinson P, Boussaid I, Decroocq J, Chouchana L, Birsen G, Barrois M, et al.
Lancet Haematol
. 2024 Oct;
11(11):e850-e861.
PMID: 39389070
Background: Pregnancy-associated haematological malignancy is a rare event; therefore, data available to guide the treatment are scarce. We aimed to evaluate the incidence, overall survival, and maternal morbidity and mortality...
3.
Vigneron C, Devautour C, Charpentier J, Birsen R, Jamme M, Pene F
Ann Intensive Care
. 2024 Oct;
14(1):155.
PMID: 39373939
Background: Bleeding events are common complications in critically ill patients with haematological malignancies. The objective of this study was to assess the incidence and identify determinants of ICU-acquired severe bleeding...
4.
Loap P, De Marzi L, Decroocq J, Birsen R, Johnson N, Deau Fischer B, et al.
Int J Part Ther
. 2024 Aug;
13:100110.
PMID: 39091405
Purpose: Effective dose to circulating immune cells (EDIC) is associated with survival in lung and esophageal cancer patients. This study aimed to evaluate the benefit of intensity-modulated proton therapy (IMPT)...
5.
Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, et al.
Sci Transl Med
. 2024 Jul;
16(757):eadk1731.
PMID: 39047119
Acute myeloid leukemia (AML) remains a challenging hematological malignancy with poor prognosis and limited treatment options. Leukemic stem cells (LSCs) contribute to therapeutic failure, relapse, and adverse outcome. This study...
6.
Loap P, Johnson N, Birsen R, Decroocq J, Kirova Y
Strahlenther Onkol
. 2024 Jul;
200(11):983-985.
PMID: 38955824
Glofitamab, an anti-CD20 antibody, is approved as a third-line treatment for relapsed or refractory (r/r) diffuse large-cell B lymphoma (DLBCL), achieving a complete response in nearly 40% of patients. This...
7.
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, et al.
Leukemia
. 2024 Apr;
38(5):1131-1142.
PMID: 38575672
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering...
8.
Carves S, Birsen R, Avouac J
Joint Bone Spine
. 2024 Jan;
91(3):105693.
PMID: 38246576
No abstract available.
9.
Birsen R, Lauture L, Sarry J, Tamburini J
Med Sci (Paris)
. 2023 Dec;
39(12):917-920.
PMID: 38108717
No abstract available.
10.
Birsen R, Pinson P, Chouchana L, Boussaid I, Treluyer J
Lancet Haematol
. 2023 Aug;
10(9):e705.
PMID: 37652595
No abstract available.